Biortus USA, Inc.

12/01/2025

Biortus is proud to announce the successful determination of the human adenosine receptor A3AR in complex with the ligand CF101 in its active conformation at an outstanding 2.81 Å resolution using cryo-electron microscopy (Cryo-EM).

The A3AR–CD39 signaling axis plays a critical role in brain repair associated with vascular dementia (VaD). CF101 (Piclidenoson)—a selective A3AR agonist currently in Phase III clinical trials for psoriasis—has demonstrated the ability to promote brain tissue regeneration and improve memory and motor function, pointing to a promising therapeutic strategy for VaD.

The A3AR–CF101 cryo-EM structure solved by Biortus (EMD-66627, 2.81 Å) is the highest-resolution structure available in this receptor family within the EMDB. The map resolves side-chain interactions within the A3AR binding pocket with exceptional clarity, revealing how CF101 engages and activates the receptor—providing an important structural framework for understanding CF101-mediated signaling and receptor activation.

This achievement further strengthens Biortus’s position as a global leader in structural biology and drug discovery. As the world’s largest commercial Cryo-EM facility, Biortus is equipped with multiple Titan Krios G4 instruments, supported by Glacios, Talos, and TF20 platforms, and a team of expert scientists experienced in solving atomic-resolution structures of large and complex biomolecules.

🔬 Want to explore more of our Cryo-EM work?
Contact us at [email protected], or visit the Biortus YouTube channel to explore our Cryo-EM playlist and other high-resolution breakthroughs: 👉 https://www.youtube.com//playlists

10/27/2025

🚀 New Structure Release from Biortus Structural Biology Library

We’re excited to share the high-resolution crystal structure of LANCL2 (Lanthionine Synthetase C-Like Protein 2), solved at 2.15 Å by X-ray crystallography.

🧬 Why LANCL2 matters
LANCL2 is an abscisic acid (ABA) receptor expressed in immune, epithelial, and muscle cells. It regulates insulin sensitivity, glucose metabolism, and immune responses through NF-κB inhibition.
Its dysregulation has been linked to metabolic disorders, inflammatory diseases, and cancer — making this structure a valuable foundation for LANCL2-targeted drug discovery.

🔬 Biortus X-ray Crystallography Advantages
✅ 3,000+ crystallization conditions with robotic setup
✅ Weekly synchrotron beamline access for rapid data collection
✅ Proven partner in structure-based drug design (SBDD)

🎥 Explore more Biortus structures on YouTube:
👉 Biortus Structural Biology Channel

📩 Contact us: [email protected] | [email protected]

10/14/2025

🚀 New Structure Release from Biortus!

We’re thrilled to announce the addition of NIK (NF-κB–inducing kinase) to the Biortus Structural Biology Library — resolved at 2.9 Å using X-ray crystallography.

🧬 Why it matters:
NIK regulates the noncanonical NF-κB pathway, influencing immune responses, viral replication, and cancer development. This new high-resolution structure (including its ligand-bound complex) opens doors for structure-based drug design (SBDD) targeting NIK.

✨ Why Biortus:

3,000+ crystallization conditions

Weekly synchrotron access

Fast, high-quality results for SBDD projects

📺 Learn more: https://www.youtube.com//playlists
📧 Contact: [email protected] | [email protected]

09/29/2025

Team Biortus is heading to BioJapan 2025!

We’re thrilled to be part of BioJapan 2025 – Asia’s premier bio-industry partnering event – taking place in Yokohama, Japan, October 8–10.

📍 Visit us at Booth C29 to meet our colleagues Minqi Gao and Dr. Yifan Hu, and explore the latest advancements in Biortus’s services, products, and platforms. Don’t miss the opportunity to discuss how our innovative solutions can accelerate your drug discovery journey.

We look forward to seeing you in Yokohama!

📩 Schedule a meeting: [email protected]

09/09/2025

🎉 Exciting News — Biortus Brand-New Website is LIVE! 🚀

New Vision. New Possibilities.

We’re thrilled to introduce our new digital home — designed to give you a seamless experience exploring who we are and what we do:

✨ BiortusAI – From Prediction to Precision: Integrating Protein Design, Antibody Optimization & Lead Molecule Discovery.
✨ Four Platforms, Total Control – End-to-end workflow integration: Gene Synthesis → Protein Production → Assay & Screening → X-ray Crystallography → Cryo-EM.
✨ Product Hub, Now Live! – Your instant access to breakthrough science: 6000+ Recombinant Proteins, 300+ Membrane Proteins, 30+ Assay Kits, 20+ Tool Enzymes.

While our look has evolved, our mission remains the same: to empower drug discovery teams with the expertise, tools, and trusted partnerships needed to overcome today’s toughest structural biology challenges.

👉 Explore the new site: www.biortus.bio — your one-stop solution, now at your fingertips.

09/08/2025

Meet Team Biortus at the Discovery on Target (DOT) Conference in Boston, MA!

We’re excited to sponsor Discovery on Target (DOT) 2025, where top scientists and innovators spotlight the latest hot targets and the technologies driving the future of drug discovery.
📍 Sheraton Boston, MA
📅 Sept 22–25, 2025

👉 Meet Team Biortus at Booth #313 — let’s talk about how we can advance discovery together!

🎤 Don’t miss our talk, Dr. Daniel Turman, Sr. Director of Business Development, presenting:“Tapping into Structure-Enabled Drug Discovery Targeting GPCRs”
📆 Thursday, Sept 25 | 12:45–1:00 PM

Let’s connect, collaborate, and shape the next chapter of drug discovery! 📩 Reach us at [email protected]

09/02/2025

Mass photometry is a cutting-edge biophysical technique that directly measures the mass of individual molecules in solution. This label-free, single-molecule method uses light scattering to detect molecular mass without the need for immobilization or tagging—making it ideal for studying biomolecular interactions, protein complexes, and viral vectors.

Applications of Mass Photometry
*Measuring the molecular mass of single biomolecules
*Determining oligomerization states
*Screening buffer conditions
*Characterizing sample heterogeneity
*Monitoring sample stability
*Investigating biomolecular interactions

In this video, we showcase four applications:
*Apoferritin gene-to-structure workflow
*Critical Aggregation Concentration (CAC) detection
*PROTAC characterization
*Molecular glue analysis

Why Choose Biortus Assay and Screening?
*Professional experimental design ensures data reliability
*Advanced SPR platforms (Biacore 8K/S200) enable high-throughput screening
*In-depth data analysis accelerates R&D progress

📩 Want to learn more? Contact us at [email protected] or [email protected]

08/25/2025

Biortus Structural Biology Library – New Release
Protein: PCSK9 | Resolution: 1.95 Å | Method: X-ray Diffraction

Biortus is pleased to announce the release of the crystal structure of PCSK9, resolved at 1.95 Å using X-ray crystallography.

🔬 Why PCSK9 Matters
PCSK9 is a serine protease secreted primarily by the liver and plays a central role in cholesterol metabolism by regulating low-density lipoprotein receptor (LDLR) levels on hepatocyte surfaces. Dysregulation of PCSK9 is strongly associated with cardiovascular diseases, including atherosclerosis, coronary heart disease, and hypercholesterolemia.

Our newly resolved high-resolution apo PCSK9 structure, combined with Biortus’s expertise in PCSK9–compound complex studies, offers valuable structural insights to support the development of small-molecule PCSK9 inhibitors.

🧪 Why Partner with Biortus for X-ray Crystallography?
✅ High-Throughput Crystallization Screening
• 3000+ unique conditions
• Robotic, nanoliter-scale precision setup
• Automated imaging & monitoring

✅ Weekly Global Synchrotron Access
• Partnerships with leading beamlines for rapid data collection

✅ Trusted Expertise in Structure-Based Drug Design (SBDD)
• Fast turnaround times
• High-resolution results
• Proven track record delivering actionable structural insights

📧 Learn More
Contact us: [email protected] | [email protected]

08/19/2025

Biortus Launches BiortusAI, an AI/ML-Powered R&D Platform for Protein, Antibody & Hit Discovery Design. Please read the article to learn more!

Biortus Launches an AI/ML-Powered R&D Platform for Protein, Antibody & Hit Discovery Design. Amid the rapid convergence of AI/ML and Structural Biology, Biortus has launched an integrated Structural Biology and AI/ML computational platform, BiortusAI. BiortusAI combines 3 core capabilities - Protein...

08/04/2025

Cryo-EM in Practice: Characterizing Lipid Nanoparticles (LNPs)

Lipid nanoparticles (LNPs) are powerful delivery systems, valued in biomedical research for their biocompatibility, versatility in encapsulating diverse molecules, and efficient cellular delivery. However, their soft, heterogeneous nature and sensitivity to dehydration and staining make them difficult to characterize using conventional techniques like traditional EM or AFM.

Cryo-electron microscopy (Cryo-EM) offers a powerful alternative. By rapidly freezing samples in vitreous ice and imaging under cryogenic conditions, Cryo-EM enables:

✅ Native morphology preservation
✅ Visualization of internal structures and lamellarity
✅ Elimination of collapse or staining artifacts

🔬 What Can Cryo-EM Reveal About LNPs?
✅ Size and shape
✅ Internal morphology
✅ Lamellarity
✅ Particle integrity
✅ Batch-to-batch consistency

🎥 This week at Biortus: Go behind the scenes of our Cryo-EM workflow for LNPs! Watch our latest video for a step-by-step look at how we achieve high-resolution characterization.

📧 Questions? Reach out to us:
[email protected] | [email protected]